Gemma Salvadó, Sharon A Brangman, and Argonde van Harten explore what the latest developments from AAIC 2024 mean for clinical practice. How can blood-based biomarkers best be applied? What should you consider when selecting patients for amyloid-targeting therapies?
14-08-2024 | Alzheimer's Disease | Panel Discussion | Article | Supported by: Lilly